A PHARMACOKINETIC AND PHARMACOGENETIC STUDY OF ALISERTIB COMBINED WITH IRINOTECAN AND TEMOZOLOMIDE IN CHILDREN AND ADOLESCENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA.

被引：0

作者：

Kudgus, R. A. ^{[1
]}

Fox, E. ^{[2
]}

McGovern, R. M. ^{[1
]}

Moorthy, G. ^{[2
]}

Marachelian, A. ^{[3
]}

DuBois, S. G. ^{[4
]}

Reid, J. M. ^{[1
]}

机构：

[1] Mayo Clin, Rochester, MN USA

[2] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA

[3] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA

[4] Univ Calif San Francisco, San Francisco, CA 94143 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PII-031

引用

页码：S68 / S68

页数：1

共 50 条

[31] Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study
Di Giannatale, Angela
Dias-Gastellier, Nathalie
Devos, Annick
Mc Hugh, Kieran
Boubaker, Ariane
Courbon, Frederic
Verschuur, Arnaud
Ducassoul, Stephane
Malekzadeh, Katty
Casanova, Michela
Amoroso, Loredana
Chastagner, Pascal
Zwaan, Christian M.
Munzer, Caroline
Aerts, Isabelle
Landman-Parker, Judith
Riccardi, Riccardo
Le Deley, Marie-Cecile
Geoerger, Birgit
Rubie, Herve
EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 170 - 177
[32] Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial
Corbacioglu, Selim
Lode, Holger
Ellinger, Susanne
Zeman, Florian
Suttorp, Meinolf
Escherich, Gabriele
Bochennek, Konrad
Gruhn, Bernd
Lang, Peter
Rohde, Marius
Debatin, Klaus Michael
Steinbach, Daniel
Beilken, Andreas
Ladenstein, Ruth
Spachtholz, Rainer
Heiss, Peter
Hellwig, Dirk
Troeger, Anja
Koller, Michael
Menhart, Karin
Riemenschneider, Markus J.
Zoubaa, Saida
Kietz, Silke
Jakob, Marcus
Sommer, Gunhild
Heise, Tilman
Hundsdoerfer, Patrick
Kuehnle, Ingrid
Dilloo, Dagmar
Schoenberger, Stefan
Schwabe, Georg
von Luettichau, Irene
Graf, Norbert
Schlegel, Paul-Gerhardt
Fruehwald, Michael
Jorch, Norbert
Paulussen, Michael
Schneider, Dominik T.
Metzler, Markus
Leipold, Alfred
Nathrath, Michaela
Imschweiler, Thomas
Christiansen, Holger
Schmid, Irene
Crazzolara, Roman
Niktoreh, Naghmeh
Cario, Gunnar
Faber, Joerg
Demmert, Martin
Babor, Florian
LANCET ONCOLOGY, 2024, 25 (07): : 922 - 932
[33] Irinotecan-temozolomide with temsirolimus or dinutuximab Crosstafark in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
Mody, Rajen
Naranjo, Arlene
Van Ryn, Collin
Yu, Alice L.
London, Wendy B.
Shulkin, Barry L.
Parisi, Marguerite T.
Servaes, Sabah-E-Noor
Diccianni, Mitchell B.
Sondel, Paul M.
Bender, Julia Glade
Maris, John M.
Park, Julie R.
Bagatell, Rochelle
LANCET ONCOLOGY, 2017, 18 (07): : 946 - 957
[34] Randomized Phase 2 Trial of the Combination of Vincristine and Irinotecan With or Without Temozolomide, in Children and Adults with Refractory or Relapsed Rhabdomyosarcoma (RMS)
Defachelles, A. S.
Bogart, E.
Casanova, M.
Merks, H.
Bisogno, G.
Calareso, G.
Gallego, S.
Gatz, S.
Le Deley, M. C.
Mc Hugh, K.
Probst, A.
Rocourt, N.
Van Rijn, R.
Wheatley, K.
Minard-Colin, V.
Chisholm, J.
PEDIATRIC BLOOD & CANCER, 2019, 66 : S5 - S6
[35] Randomized phase 2 trial of the combination of vincristine and irinotecan with or without temozolomide, in children and adults with refractory or relapsed rhabdomyosarcoma (RMS).
Defachelles, Anne Sophie
Bogart, Emilie
Casanova, Michela
Merks, Hans
Bisogno, Gianni
Calareso, Giuseppina
Melcon, Soledad Gallego
Gatz, Susanne
Le Deley, Marie-Cecile
McHugh, Kieran
Probst, Alicia
Rocourt, Nathalie
van Rijn, Rick R.
Wheatley, Keith
Minard-Colin, Veronique
Chisholm, Julia
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[36] Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma
Mody, Rajen
Zhao, Lili
Yanik, Gregory Anthony
Opipari, Valerie
PEDIATRIC BLOOD & CANCER, 2017, 64 (11)
[37] A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma - BEACON-Neuroblastoma, a European Innovative Therapies for Children with Cancer (ITCC) - International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.
Moreno, Lucas
Laidler, Jennifer
Moroz, Veronica
Owens, Cormac
Rubie, Herve
Berlanga, Pablo
Castellano, Aurora
Nysom, Karsten
Ladenstein, Ruth L.
Rossler, Jochen
Zwaan, Christian M.
Elliott, Martin
Makin, Guy
Murphy, Dermot
Burchill, Susan A.
Jerome, Neil
Rousseau, Raphael F.
Kearns, Pamela
Wheatley, Keith
Pearson, Andrew D. J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[38] Phase I study of oral irinotecan, temozolomide, and vincristine for children with refractory solid tumors: A Children's Oncology Group study
Perentesis, J. P.
Wagner, L. M.
Ames, M. M.
Reid, J. M.
Stewart, C. F.
Ingle, A. M.
Blaney, S. M.
Adamson, P. C.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[39] Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
DuBois, Steven G.
Chesler, Louis
Groshen, Susan
Hawkins, Randall
Goodarzian, Fariba
Shimada, Hiroyuki
Yanik, Greg
Tagen, Michael
Stewart, Clinton
Mosse, Yael P.
Maris, John M.
Tsao-Wei, Denice
Marachelian, Araz
Villablanca, Judith G.
Matthay, Katherine K.
CLINICAL CANCER RESEARCH, 2012, 18 (09) : 2679 - 2686
[40] Phase I study of temozolomide in combination with topotecan (TOTEM) in children with refractory or relapsed malignant tumors
Rubie, H.
Frappaz, D.
Defachelles, A.
Ndiaye, A.
Dias, N.
Aerts, I.
Gentet, J.
Djafari, L.
Jaworski, M.
Vassal, G.
Geoerger, B.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →